boosh foods

Boosh Plant-Based Brands Closes $1,250,000 Private Placement

Boosh Plant-Based Brands Inc.  (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") is pleased to announce that on Monday, November 8th it closed a private placement in the amount of $1,250,000. One strategic investor subscriber for 1,250,000 units at a price of $1.00 per unit, each unit consisting of one common share and one warrant exercisable at $1.35 per share until November 8, 2024.

Aggregate finder's fees of $125,000 payable through the issuance of 125,000 units on the same terms as the placement units and the issuance of 125,000 broker's warrants exercisable to acquire units at a price of $1.00 per unit until November 8, 2024 were issued.

All securities issued in the private placement are subject to a four month hold period expiring on March 9, 2022.

The proceeds from the private placement will be used for general working capital, ongoing product development and future plant-based acquisition opportunities.

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer
Telephone: (833) 882-6674
www.Booshfood.com

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. We currently offer six frozen meals and three refrigerated meals which are sold throughout Canada. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102528

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million, before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.

As previously stated, the Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

5 Top NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching a high of 4,954.813 on September 19.

While the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.5 percent from now to 2034, reaching a valuation of US$4.61 trillion.

Keep reading...Show less
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Elixinol Wellness Limited

Strategic Acquisition and Capital Raising - Investor Presentation | 3 October 2024

Elixinol Wellness Ltd. (”EXL”) has entered into a binding agreement to acquire 100% of the business assets from the entities ("Acquisition") that together form The Healthy Chef business ("Healthy Chef").

Keep reading...Show less
Radiopharm Theranostics

Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce regulatory and manufacturing progress for its B7-H3 targeting radio-antibody, BetaBart.

Keep reading...Show less
Hydralyte

Completion of Divesture of Non-US Assets

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte US” or “the Company”) refers to its announcement released pre-open on 2 October 2024 regarding entry into an Intellectual Property Sales Agreement (the ‘Agreement’) and related documents with Prestige Consumer Healthcare Inc. and associated subsidiaries.

Keep reading...Show less

Latest Press Releases

Related News

×